{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:41:27Z","timestamp":1784864487998,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11060-026-05599-z","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:12:33Z","timestamp":1778926353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A review of targeted therapies for NF2-related vestibular schwannoma: molecular pathogenesis, emerging therapeutics, and future clinical horizons"],"prefix":"10.1007","volume":"178","author":[{"given":"Morgan K.","family":"Sokol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9272-019X","authenticated-orcid":false,"given":"Lily H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"5599_CR1","volume-title":"Neurofibromatosis Type 2. StatPearls","author":"R Tiwari","year":"2025","unstructured":"Tiwari R, Singh AK (2025) Neurofibromatosis Type 2. StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"5599_CR2","doi-asserted-by":"publisher","unstructured":"Mautner V-F, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study 2002. https:\/\/doi.org\/10.3171\/jns.2002.96.2.0223","DOI":"10.3171\/jns.2002.96.2.0223"},{"key":"5599_CR3","volume-title":"NF2-Related Schwannomatosis","author":"DG Evans","year":"1993","unstructured":"Evans DG (1993) In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, GeneReviews\u00ae (eds) NF2-Related Schwannomatosis. University of Washington, Seattle, Seattle (WA)"},{"key":"5599_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11060-022-04061-0","volume":"159","author":"I Gugel","year":"2022","unstructured":"Gugel I, Grimm F, Tatagiba M, Schuhmann MU, Zipfel J (2022) Management of neurofibromatosis type 2 and schwannomatosis associated peripheral and intraspinal schwannomas: influence of surgery, genetics, and localization. J Neurooncol 159:271\u2013279. https:\/\/doi.org\/10.1007\/s11060-022-04061-0","journal-title":"J Neurooncol"},{"key":"5599_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/neuonc\/nou317","volume":"17","author":"R Dewan","year":"2015","unstructured":"Dewan R, Pemov A, Kim HJ, Morgan KL, Vasquez RA, Chittiboina P et al (2015) Evidence of polyclonality in neurofibromatosis type 2\u2013associated multilobulated vestibular schwannomas. Neuro-Oncol 17:566\u2013573. https:\/\/doi.org\/10.1093\/neuonc\/nou317","journal-title":"Neuro-Oncol"},{"key":"5599_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791\u2013800. https:\/\/doi.org\/10.1016\/0092-8674(93)90406-G","journal-title":"Cell"},{"key":"5599_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515\u2013521. https:\/\/doi.org\/10.1038\/363515a0","journal-title":"Nature"},{"key":"5599_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2174\/138920310791824011","volume":"11","author":"I Stamenkovic","year":"2010","unstructured":"Stamenkovic I, Yu Q (2010) Merlin, a Magic Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival. Curr Protein Pept Sci 11:471\u2013484. https:\/\/doi.org\/10.2174\/138920310791824011","journal-title":"Curr Protein Pept Sci"},{"key":"5599_CR9","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1038\/onc.2010.363","volume":"29","author":"KD Hadfield","year":"2010","unstructured":"Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT et al (2010) Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216\u20136221. https:\/\/doi.org\/10.1038\/onc.2010.363","journal-title":"Oncogene"},{"key":"5599_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/glia.22391","volume":"60","author":"S Ammoun","year":"2012","unstructured":"Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E et al (2012) The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Glia 60:1721\u20131733. https:\/\/doi.org\/10.1002\/glia.22391","journal-title":"Glia"},{"key":"5599_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/hmg\/11.1.69","volume":"11","author":"KMM Schulze","year":"2002","unstructured":"Schulze KMM, Hanemann CO, M\u00fcller HW, Hanenberg H (2002) Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 11:69\u201376. https:\/\/doi.org\/10.1093\/hmg\/11.1.69","journal-title":"Hum Mol Genet"},{"key":"5599_CR12","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1038\/onc.2015.404","volume":"35","author":"L Zhou","year":"2016","unstructured":"Zhou L, Lyons-Rimmer J, Ammoun S, M\u00fcller J, Lasonder E, Sharma V et al (2016) The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. Oncogene 35:3443\u20133453. https:\/\/doi.org\/10.1038\/onc.2015.404","journal-title":"Oncogene"},{"key":"5599_CR13","doi-asserted-by":"publisher","unstructured":"Felley-Bosco E, Stahel R (2014) Hippo\/YAP pathway for targeted therapy. Transl Lung Cancer Res 3. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.02.03","DOI":"10.3978\/j.issn.2218-6751.2014.02.03"},{"key":"5599_CR14","doi-asserted-by":"publisher","unstructured":"Chen Z, Li S, Mo J, Hawley E, Wang Y, He Y et al Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS\/MAPK signaling. JCI Insight 2020;5. https:\/\/doi.org\/10.1172\/jci.insight.141514","DOI":"10.1172\/jci.insight.141514"},{"key":"5599_CR15","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1080\/00016480310005101","volume":"123","author":"J Brieger","year":"2003","unstructured":"Brieger J, Bedavanija A, Lehr H-A, Maurer J, Mann WJ (2003) Expression of Angiogenic Growth Factors in Acoustic Neurinoma. Acta Otolaryngol (Stockh) 123:1040\u20131045. https:\/\/doi.org\/10.1080\/00016480310005101","journal-title":"Acta Otolaryngol (Stockh)"},{"key":"5599_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1097\/00005537-200312000-00014","volume":"113","author":"P Cay\u00e9-Thomasen","year":"2003","unstructured":"Cay\u00e9-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup S-E (2003) Immunohistochemical Demonstration of Vascular Endothelial Growth Factor in Vestibular Schwannomas Correlates to Tumor Growth Rate. Laryngoscope 113:2129\u20132134. https:\/\/doi.org\/10.1097\/00005537-200312000-00014","journal-title":"Laryngoscope"},{"key":"5599_CR17","doi-asserted-by":"publisher","first-page":"eabn2611","DOI":"10.1126\/sciadv.abn2611","volume":"8","author":"JH Bae","year":"2022","unstructured":"Bae JH, Yang MJ, Jeong S, Kim J, Hong SP, Kim JW et al (2022) Gatekeeping role of Nf2\/Merlin in vascular tip EC induction through suppression of VEGFR2 internalization. Sci Adv 8:eabn2611. https:\/\/doi.org\/10.1126\/sciadv.abn2611","journal-title":"Sci Adv"},{"key":"5599_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A et al (2009) Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2. N Engl J Med 361:358\u2013367. https:\/\/doi.org\/10.1056\/NEJMoa0902579","journal-title":"N Engl J Med"},{"key":"5599_CR19","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T et al (2019) Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol Off J Am Soc Clin Oncol 37:3446\u20133454. https:\/\/doi.org\/10.1200\/JCO.19.01367","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5599_CR20","doi-asserted-by":"publisher","first-page":"54515","DOI":"10.18632\/oncotarget.10248","volume":"7","author":"S Troutman","year":"2016","unstructured":"Troutman S, Moleirinho S, Kota S, Nettles K, Fallahi M, Johnson GL et al (2016) Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1. Oncotarget 7:54515\u201354525. https:\/\/doi.org\/10.18632\/oncotarget.10248","journal-title":"Oncotarget"},{"key":"5599_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00439-016-1753-8","volume":"136","author":"H Kehrer-Sawatzki","year":"2017","unstructured":"Kehrer-Sawatzki H, Farschtschi S, Mautner V-F, Cooper DN (2017) The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet 136:129\u2013148. https:\/\/doi.org\/10.1007\/s00439-016-1753-8","journal-title":"Hum Genet"},{"key":"5599_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","volume":"88","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT et al (2017) Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 88:87\u201392. https:\/\/doi.org\/10.1212\/WNL.0000000000003418","journal-title":"Neurology"},{"key":"5599_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841\u2013844. https:\/\/doi.org\/10.1038\/362841a0","journal-title":"Nature"},{"key":"5599_CR24","first-page":"921","volume":"56","author":"O Melnyk","year":"1996","unstructured":"Melnyk O, Shuman MA, Kim KJ (1996) Vascular Endothelial Growth Factor Promotes Tumor Dissemination by a Mechanism Distinct from Its Effect on Primary Tumor Growth. Cancer Res 56:921\u2013924","journal-title":"Cancer Res"},{"key":"5599_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1593\/neo.111600","volume":"14","author":"H-K Wong","year":"2012","unstructured":"Wong H-K, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AW, di Tomaso E et al (2012) Merlin\/NF2 Regulates Angiogenesis in Schwannomas through a Rac1\/Semaphorin 3F-Dependent Mechanism. Neoplasia N Y N 14:84\u201394. https:\/\/doi.org\/10.1593\/neo.111600","journal-title":"Neoplasia N Y N"},{"key":"5599_CR26","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/neuonc\/noad066","volume":"25","author":"SR Plotkin","year":"2023","unstructured":"Plotkin SR, Allen J, Dhall G, Campian JL, Clapp DW, Fisher MJ et al (2023) Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncol 25:1498\u20131506. https:\/\/doi.org\/10.1093\/neuonc\/noad066","journal-title":"Neuro-Oncol"},{"key":"5599_CR27","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A et al (2016) Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol Off J Am Soc Clin Oncol 34:1669\u20131675. https:\/\/doi.org\/10.1200\/JCO.2015.64.3817","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5599_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-015-3604-y","author":"S Farschtschi","year":"2015","unstructured":"Farschtschi S, Kollmann P, Dalchow C, Stein A, Mautner V-F (2015) Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Head Neck Surg 272:3857\u20133860. https:\/\/doi.org\/10.1007\/s00405-015-3604-y. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol -"},{"key":"5599_CR29","doi-asserted-by":"publisher","first-page":"e28228","DOI":"10.1002\/pbc.28228","volume":"67","author":"S Renzi","year":"2020","unstructured":"Renzi S, Michaeli O, Salvador H, Alderete D, Ponce NF, Zapotocky M et al (2020) Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr Blood Cancer 67:e28228. https:\/\/doi.org\/10.1002\/pbc.28228","journal-title":"Pediatr Blood Cancer"},{"key":"5599_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2176\/nmc.oa.2019-0194","volume":"60","author":"M Fujii","year":"2020","unstructured":"Fujii M, Ichikawa M, Iwatate K, Bakhit M, Yamada M, Kuromi Y et al (2020) Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients. Neurol Med Chir (Tokyo) 60:75\u201382. https:\/\/doi.org\/10.2176\/nmc.oa.2019-0194","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"5599_CR31","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","volume":"272","author":"MC Alanin","year":"2015","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L et al (2015) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol 272:3627\u20133633. https:\/\/doi.org\/10.1007\/s00405-014-3398-3","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"5599_CR32","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ et al (2012) Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2: A Retrospective Review of 31 Patients. Otol Neurotol 33:1046. https:\/\/doi.org\/10.1097\/MAO.0b013e31825e73f5","journal-title":"Otol Neurotol"},{"key":"5599_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1055\/s-0038-1676628","volume":"80","author":"DE Killeen","year":"2019","unstructured":"Killeen DE, Klesse L, Tolisano AM, Hunter JB, Kutz JW (2019) Long-Term Effects of Bevacizumab on Vestibular Schwannoma Volume in Neurofibromatosis Type 2 Patients. J Neurol Surg Part B Skull Base 80:540\u2013546. https:\/\/doi.org\/10.1055\/s-0038-1676628","journal-title":"J Neurol Surg Part B Skull Base"},{"key":"5599_CR34","doi-asserted-by":"publisher","unstructured":"Gugel I, Kluwe L, Zipfel J, Teuber C, Tatagiba M, Mautner V-F et al Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients. Cancers 2019;11. https:\/\/doi.org\/10.3390\/cancers11121862","DOI":"10.3390\/cancers11121862"},{"key":"5599_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","volume":"124","author":"A Hochart","year":"2015","unstructured":"Hochart A, Gaillard V, Baroncini M, Andr\u00e9 N, Vannier J-P, Vinchon M et al (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 124:229\u2013236. https:\/\/doi.org\/10.1007\/s11060-015-1828-8","journal-title":"J Neurooncol"},{"key":"5599_CR36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","volume":"73","author":"KM Slusarz","year":"2014","unstructured":"Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR (2014) Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73:1197\u20131204. https:\/\/doi.org\/10.1007\/s00280-014-2456-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"5599_CR37","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cancers16081479","volume":"16","author":"JPJ Douwes","year":"2024","unstructured":"Douwes JPJ, Hensen EF, Jansen JC, Gelderblom H, Schopman JE (2024) Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience. Cancers 16:1479. https:\/\/doi.org\/10.3390\/cancers16081479","journal-title":"Cancers"},{"key":"5599_CR38","doi-asserted-by":"publisher","first-page":"W11","DOI":"10.2214\/AJR.13.12412","volume":"204","author":"A Kambadakone","year":"2015","unstructured":"Kambadakone A, Yoon SS, Kim T-M, Karl DL, Duda DG, DeLaney TF et al (2015) CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression. Am J Roentgenol 204:W11\u2013W18. https:\/\/doi.org\/10.2214\/AJR.13.12412","journal-title":"Am J Roentgenol"},{"key":"5599_CR39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.21147\/j.issn.1000-9604.2019.04.03","volume":"31","author":"X Liang","year":"2019","unstructured":"Liang X, Li H, Coussy F, Callens C, Lerebours F (2019) An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress? Chin J Cancer Res 31:586\u2013600. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2019.04.03","journal-title":"Chin J Cancer Res"},{"key":"5599_CR40","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.23.02376","volume":"42","author":"R Tamura","year":"2024","unstructured":"Tamura R, Yamanobe Y, Fujioka M, Morimoto Y, Fukumura M, Nakaya M et al (2024) Phase I\/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis. J Clin Oncol Off J Am Soc Clin Oncol 42:2578\u20132587. https:\/\/doi.org\/10.1200\/JCO.23.02376","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5599_CR41","doi-asserted-by":"publisher","first-page":"vdaf083","DOI":"10.1093\/noajnl\/vdaf083","volume":"7","author":"MR Garcia","year":"2025","unstructured":"Garcia MR, Hagiwara M, Yaffe A, Mitchell C, Akshintala S, Nicolaides T et al (2025) Phase II study of axitinib in patients with NF2-related schwannomatosis and progressive vestibular schwannomas. Neuro-Oncol Adv 7:vdaf083. https:\/\/doi.org\/10.1093\/noajnl\/vdaf083","journal-title":"Neuro-Oncol Adv"},{"key":"5599_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","volume":"67","author":"H Morrison","year":"2007","unstructured":"Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P (2007) Merlin\/Neurofibromatosis Type 2 Suppresses Growth by Inhibiting the Activation of Ras and Rac. Cancer Res 67:520\u2013527. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1608","journal-title":"Cancer Res"},{"key":"5599_CR43","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ et al (2020) Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med 382:1430\u20131442. https:\/\/doi.org\/10.1056\/NEJMoa1912735","journal-title":"N Engl J Med"},{"key":"5599_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/neuonc\/noz002","volume":"21","author":"MA Fuse","year":"2019","unstructured":"Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK et al (2019) Preclinical assessment of MEK1\/2 inhibitors for neurofibromatosis type 2\u2013associated schwannomas reveals differences in efficacy and drug resistance development. Neuro-Oncol 21:486\u2013497. https:\/\/doi.org\/10.1093\/neuonc\/noz002","journal-title":"Neuro-Oncol"},{"key":"5599_CR45","doi-asserted-by":"publisher","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","volume":"92","author":"E Kun","year":"2021","unstructured":"Kun E, Tsang YTM, Ng CW, Gershenson DM, Wong KK (2021) MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev 92:102137. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102137","journal-title":"Cancer Treat Rev"},{"key":"5599_CR46","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto M, Cole BK, Lallemand D, Liu C-H, McClatchey AI (2007) Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin. J Cell Biol 177:893\u2013903. https:\/\/doi.org\/10.1083\/jcb.200703010","journal-title":"J Cell Biol"},{"key":"5599_CR47","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG (2010) Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31:1135\u20131143. https:\/\/doi.org\/10.1097\/MAO.0b013e3181eb328a","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"key":"5599_CR48","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/neuonc\/noq012","volume":"12","author":"S Ammoun","year":"2010","unstructured":"Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D et al (2010) ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma\u2020. Neuro-Oncol 12:834\u2013843. https:\/\/doi.org\/10.1093\/neuonc\/noq012","journal-title":"Neuro-Oncol"},{"key":"5599_CR49","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","volume":"29","author":"JJ Clark","year":"2008","unstructured":"Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR (2008) The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 29:846\u2013853. https:\/\/doi.org\/10.1097\/MAO.0b013e31817f7398","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"key":"5599_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/MAO.0b013e31821f7d88","volume":"32","author":"ZK Ahmad","year":"2011","unstructured":"Ahmad ZK, Brown CM, Cueva RA, Ryan AF, Doherty JK (2011) ErbB Expression, Activation, and Inhibition With Lapatinib and Tyrphostin (AG825) in Human Vestibular Schwannomas. Otol Neurotol 32:841. https:\/\/doi.org\/10.1097\/MAO.0b013e31821f7d88","journal-title":"Otol Neurotol"},{"key":"5599_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/ncponc1157","volume":"5","author":"SR Plotkin","year":"2008","unstructured":"Plotkin SR, Singh MA, O\u2019Donnell CC, Harris GJ, McClatchey AI, Halpin C (2008) Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol 5:487\u2013491. https:\/\/doi.org\/10.1038\/ncponc1157","journal-title":"Nat Clin Pract Oncol"},{"key":"5599_CR52","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO et al (2012) Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 14:1163\u20131170. https:\/\/doi.org\/10.1093\/neuonc\/nos146","journal-title":"Neuro-Oncol"},{"key":"5599_CR53","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3171\/2022.9.JNS22699","volume":"138","author":"F Zhao","year":"2023","unstructured":"Zhao F, Li S-W, Zhang S, Li P, Zhao C, Zhao X-B et al (2023) Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Neurosurg 138:1680\u20131687. https:\/\/doi.org\/10.3171\/2022.9.JNS22699","journal-title":"J Neurosurg"},{"key":"5599_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.drup.2007.03.003","volume":"10","author":"G Tortora","year":"2007","unstructured":"Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR et al (2007) Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10:81\u2013100. https:\/\/doi.org\/10.1016\/j.drup.2007.03.003","journal-title":"Drug Resist Updat"},{"key":"5599_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/COC.0000000000000976","volume":"46","author":"J Deluce","year":"2023","unstructured":"Deluce J, Maj D, Verma S, Breadner D, Boldt G, Raphael J (2023) Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non\u2013small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis. Am J Clin Oncol 46:87. https:\/\/doi.org\/10.1097\/COC.0000000000000976","journal-title":"Am J Clin Oncol"},{"key":"5599_CR56","doi-asserted-by":"publisher","first-page":"31666","DOI":"10.18632\/oncotarget.15912","volume":"8","author":"AM Petrilli","year":"2017","unstructured":"Petrilli AM, Garcia J, Bott M, Klingeman Plati S, Dinh CT, Bracho OR et al (2017) Ponatinib promotes a G1 cell-cycle arrest of merlin\/NF2-deficient human schwann cells. Oncotarget 8:31666\u201331681. https:\/\/doi.org\/10.18632\/oncotarget.15912","journal-title":"Oncotarget"},{"key":"5599_CR57","doi-asserted-by":"publisher","first-page":"e39412","DOI":"10.1371\/journal.pone.0039412","volume":"7","author":"N Sabha","year":"2012","unstructured":"Sabha N, Au K, Agnihotri S, Singh S, Mangat R, Guha A et al (2012) Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PLoS ONE 7:e39412. https:\/\/doi.org\/10.1371\/journal.pone.0039412","journal-title":"PLoS ONE"},{"key":"5599_CR58","doi-asserted-by":"publisher","first-page":"bcr2013010274","DOI":"10.1136\/bcr-2013-010274","volume":"2013","author":"S Lim","year":"2013","unstructured":"Lim S, de Souza P (2013) Imatinib in neurofibromatosis type 2. Case Rep 2013:bcr2013010274. https:\/\/doi.org\/10.1136\/bcr-2013-010274","journal-title":"Case Rep"},{"key":"5599_CR59","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO et al (2009) NF2\/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth. Mol Cell Biol 29:4250\u20134261. https:\/\/doi.org\/10.1128\/MCB.01581-08","journal-title":"Mol Cell Biol"},{"key":"5599_CR60","first-page":"471","volume":"6","author":"AM Petrilli","year":"2014","unstructured":"Petrilli AM, Fuse MA, Donnan MS, Bott M, Sparrow NA, Tondera D et al (2014) A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. Am J Transl Res 6:471\u2013493","journal-title":"Am J Transl Res"},{"key":"5599_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/neuonc\/not242","volume":"16","author":"M Giovannini","year":"2014","unstructured":"Giovannini M, Bonne N-X, Vitte J, Chareyre F, Tanaka K, Adams R et al (2014) mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro-Oncol 16:493\u2013504. https:\/\/doi.org\/10.1093\/neuonc\/not242","journal-title":"Neuro-Oncol"},{"key":"5599_CR62","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.18632\/oncotarget.4858","volume":"6","author":"RL Beauchamp","year":"2015","unstructured":"Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao W-N, Jordan JT et al (2015) A high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget 6:16981\u201316997. https:\/\/doi.org\/10.18632\/oncotarget.4858","journal-title":"Oncotarget"},{"key":"5599_CR63","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D et al (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122:313\u2013320. https:\/\/doi.org\/10.1007\/s11060-014-1710-0","journal-title":"J Neurooncol"},{"key":"5599_CR64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A et al (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 16:292\u2013297. https:\/\/doi.org\/10.1093\/neuonc\/not150","journal-title":"Neuro-Oncol"},{"key":"5599_CR65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","volume":"133","author":"S Goutagny","year":"2017","unstructured":"Goutagny S, Giovannini M, Kalamarides M (2017) A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. J Neurooncol 133:443\u2013445. https:\/\/doi.org\/10.1007\/s11060-017-2447-3","journal-title":"J Neurooncol"},{"key":"5599_CR66","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","volume":"20","author":"MA Karajannis","year":"2021","unstructured":"Karajannis MA, Mauguen A, Maloku E, Xu Q, Dunbar EM, Plotkin SR et al (2021) Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. Mol Cancer Ther 20:1584\u20131591. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0143","journal-title":"Mol Cancer Ther"},{"key":"5599_CR67","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1038\/s41598-020-60156-6","volume":"10","author":"JE Sagers","year":"2020","unstructured":"Sagers JE, Beauchamp RL, Zhang Y, Vasilijic S, Wu L, DeSouza P et al (2020) Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. Sci Rep 10:4211. https:\/\/doi.org\/10.1038\/s41598-020-60156-6","journal-title":"Sci Rep"},{"key":"5599_CR68","doi-asserted-by":"publisher","first-page":"890","DOI":"10.18632\/oncotarget.28254","volume":"13","author":"J Huegel","year":"2022","unstructured":"Huegel J, Dinh CT, Martinelli M, Bracho O, Rosario R, Hardin H et al (2022) CUDC907, a dual phosphoinositide-3 kinase\/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells. Oncotarget 13:890\u2013904. https:\/\/doi.org\/10.18632\/oncotarget.28254","journal-title":"Oncotarget"},{"key":"5599_CR69","doi-asserted-by":"publisher","unstructured":"Fernandez-Valle C, Nagel A, Huegel J, Petrilli A, Rosario R, Victoria B et al Simultaneous Inhibition of PI3K and PAK in Preclinical Models of Neurofibromatosis Type 2-related Schwannomatosis. Res Sq 2023:rs.3.rs-3405297. https:\/\/doi.org\/10.21203\/rs.3.rs-3405297\/v1","DOI":"10.21203\/rs.3.rs-3405297\/v1"},{"key":"5599_CR70","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/neuonc\/noae282","volume":"27","author":"Y-H Chung","year":"2025","unstructured":"Chung Y-H, Park S, Lee M, Lee J, Ji Y, Song YJ et al (2025) Therapeutic effect of novel drug candidate, PRG-N-01, on NF2 syndrome-related tumor. Neuro-Oncol 27:1241\u20131255. https:\/\/doi.org\/10.1093\/neuonc\/noae282","journal-title":"Neuro-Oncol"},{"key":"5599_CR71","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/onc.2013.320","volume":"33","author":"A Petrilli","year":"2014","unstructured":"Petrilli A, Copik A, Posadas M, Chang L-S, Welling DB, Giovannini M et al (2014) LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene 33:3571\u20133582. https:\/\/doi.org\/10.1038\/onc.2013.320","journal-title":"Oncogene"},{"key":"5599_CR72","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.ejca.2009.03.013","volume":"45","author":"TX Lee","year":"2009","unstructured":"Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen C-S et al (2009) Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer Oxf Engl 1990 45:1709\u20131720. https:\/\/doi.org\/10.1016\/j.ejca.2009.03.013","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"5599_CR73","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/CAD.0000000000001502","volume":"34","author":"R Zhao","year":"2023","unstructured":"Zhao R, Zou W, Zhao X (2023) Treatment of neurofibromatosis type II with anlotinib: a case report and literature review. Anticancer Drugs 34:1065. https:\/\/doi.org\/10.1097\/CAD.0000000000001502","journal-title":"Anticancer Drugs"},{"key":"5599_CR74","doi-asserted-by":"publisher","first-page":"e0305121","DOI":"10.1371\/journal.pone.0305121","volume":"19","author":"D Benton","year":"2024","unstructured":"Benton D, Yee Chow H, Karchugina S, Chernoff J (2024) Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma. PLoS ONE 19:e0305121. https:\/\/doi.org\/10.1371\/journal.pone.0305121","journal-title":"PLoS ONE"},{"key":"5599_CR75","doi-asserted-by":"publisher","first-page":"e0252048","DOI":"10.1371\/journal.pone.0252048","volume":"16","author":"L-S Chang","year":"2021","unstructured":"Chang L-S, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E et al (2021) Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE 16:e0252048. https:\/\/doi.org\/10.1371\/journal.pone.0252048","journal-title":"PLoS ONE"},{"key":"5599_CR76","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","volume":"390","author":"SR Plotkin","year":"2024","unstructured":"Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL et al (2024) Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors. N Engl J Med 390:2284\u20132294. https:\/\/doi.org\/10.1056\/NEJMoa2400985","journal-title":"N Engl J Med"},{"key":"5599_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2025.15033","volume":"29","author":"Z Lin","year":"2025","unstructured":"Lin Z, Yu W, Jing F, Xu Z, Liu M, Jiao S (2025) Short\u2013term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study. Oncol Lett 29:1\u20139. https:\/\/doi.org\/10.3892\/ol.2025.15033","journal-title":"Oncol Lett"},{"key":"5599_CR78","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11060-024-04596-4","volume":"167","author":"PL Nghiemphu","year":"2024","unstructured":"Nghiemphu PL, Vitte J, Dombi E, Nguyen T, Wagle N, Ishiyama A et al (2024) Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. J Neurooncol 167:339\u2013348. https:\/\/doi.org\/10.1007\/s11060-024-04596-4","journal-title":"J Neurooncol"},{"key":"5599_CR79","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0194599818809085","volume":"160","author":"P Sverak","year":"2019","unstructured":"Sverak P, Adams ME, Haines SJ, Levine SC, Nascene D, Sommer K et al (2019) Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities. Otolaryngol\u2013Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 160:526\u2013532. https:\/\/doi.org\/10.1177\/0194599818809085","journal-title":"Otolaryngol\u2013Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg"},{"key":"5599_CR80","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/nop\/npv065","volume":"3","author":"KA Morris","year":"2016","unstructured":"Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE et al (2016) Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncol Pract 3:281\u2013289. https:\/\/doi.org\/10.1093\/nop\/npv065","journal-title":"Neuro-Oncol Pract"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05599-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:40:35Z","timestamp":1781012435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05599-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5599"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05599-z","relation":{"references":[{"id-type":"doi","id":"10.1007\/s00405-015-3604-y","asserted-by":"subject"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Author G.L. serves as a consultant to Medtronic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}